

FACT SHEET

COMPANY PROFILE

Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine. Biotest develops, manufactures and markets plasma proteins and biotherapeutic drugs. Our value chain extends from pre-clinical and clinical development to worldwide marketing and distribution. Biotest manufactures immunoglobulins, clotting factors and albumins which derive from human blood plasma. Biotest currently employs more than 1,900 people worldwide.

The most important raw material for our pharmaceuticals is human blood plasma, which we process into effective and highly purified drugs in one of our world leading fractionation facilities in Europe. These medications are used to treat life-threatening diseases such as blood coagulation disorders (haemophilia), severe infections and immune system disorders.

MANAGEMENT BOARD



Dr. Michael Ramroth
 Chairman of the Board of
 Management / Chief Financial
 Officer



Dr. Georg Floß
 Chief Operations Officer

SUPERVISORY BOARD

> **Rolf Hoffmann**

Chairman

> **Simone Fischer**

> **Kerstin Birkhahn**

> **Tan Yang**

Dep. Chairman

> **Xiaoying (David) Gao**

> **Jürgen Heilmann**


SHARE CHART OF ORDINARY SHARES



KEY DATA OF ORDINARY SHARES

ISIN	DE0005227201
WKN	522 720
Share type	Ordinary
Bloomberg Code	BIO@GR
Reuters Code	BIOG_p.DE
Ticker	BIO
Branch	Pharma
Index	Prime All Share
Segment	Prime Standard
Last Dividend	EUR 0.00 for 2020
No. of shares	19,785,726
Market Cap	EUR 668.76 mn
52 week high	EUR 34.70
52 week low	EUR 20.80
Stock exchanges	Regulated market in Frankfurt (Prime Standard); Open Market in Berlin, Dusseldorf, Hamburg/Hanover, Munich, Stuttgart, Tradegate

SHARE CHART OF PREFERENCE SHARES



KEY DATA OF PREFERENCE SHARES

ISIN	DE0005227235
WKN	522 723
Share type	Preference
Bloomberg Code	BIO@GR
Reuters Code	BIOG_p.DE
Ticker	BIO3
Branch	Pharma
Index	Prime All Share
Segment	Prime Standard
Last Dividend	EUR 0.04 for 2020
No. of shares	19,785,726
Market Cap	EUR 660.84 mn
52 week high	EUR 34.20
52 week low	EUR 19.70
Stock exchanges	Regulated market in Frankfurt (Prime Standard); Open Market in Berlin, Dusseldorf, Hamburg/Hanover, Munich, Stuttgart, Tradegate

FACT SHEET

ANNUAL FIGURES

	2014	2015	2016 ¹⁾	2017 ¹⁾	2018 ¹⁾	2019	2020
in EUR millions							
Sales	582.0	534.6	408.0	378.1	400.3	419.1	484.2
EBITDA	85.9	59.3	58.1	13.0	35.2	30.5	28.3
EBIT	53.4	37.3	35.2	(9.3)	10.6	(1.2)	(0.3)
Profit before tax	46.9	34.8	24.0	(26.0)	(6.0)	(1.3)	(30.0)
Net profit	19.2	27.0	6.1	(16.4)	(12.9)	(4.7)	(31.4)
Balance Sheet Total	1,032.6	962.7	932.8	978.5	1,042.3	1,108.4	1,131.3
Shareholders' equity	480.2	412.3	360.7	347.8	495.0	476.9	441.6
Dividend in EUR²⁾³⁾							
Ordinary shares	0.20	0.02	0.05	0.00	0.00	0.00	0.00
Preference shares	0.22	0.04	0.07	0.04	0.04	0.04	0.04
Staff⁴⁾	2,158	2,271	1,441	1,659	1,663	1,837	1,928

All figures according to IFRS

¹⁾ Continuing operations

²⁾ On 15 July 2015 Biotest AG reorganises stock exchange listing due to share split with the ration one to three. By implementing the capital increase and the share split the existing shareholder structure does not change. The share capital of Biotest AG amounted to € 33,767,639.04 before the capital increase and was divided into 6,595,242 ordinary shares and 6,595,242 preference shares without voting rights. Thus, one ordinary or preference share had a proportional amount of the share capital of € 2.56. After the implementation of the capital increase from capital funds by € 5,803,812.96 to € 39,571,452.00 without issuing new shares and the share split, each former holder of one existing ordinary or preference share now holds three ordinary or preference shares with a proportional amount of the share capital of € 1.00. After capital increase and share split the amount of ordinary shares and preference share amounts to each 19,785,726 shares. The previous year's figures have been adjusted to the new amount of shares.

³⁾ 2020: proposed at AGM on May 11, 2021

⁴⁾ in FTEs (Full time equivalents)

SHAREHOLDER STRUCTURE

Ordinary Shares:

Release according to § 21 Abs. 1 WpHG:

89.88% Tiancheng (Germany) Pharmaceutical Holdings AG
(acquisition company of the Creat Group Corporation)

3.74% Polygon Global Partners LLP

0.28% UBS Group AG

Preference Shares:

100.00% Free float

FINANCIAL CALENDAR

Aug 12, 2021 Publication half-yearly financial report

Nov 11, 2021 Publication quarterly statement (call-date Q3)

Biotest AG

Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland

Tel.: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
investor_relations@biotest.de
<http://www.biotest.de>

Contact Investor Relations

Dr. Monika Buttke
Head of Investor Relations
Telefon: +49 (0) 61 03 / 801 4406
Telefax: +49 (0) 61 03 / 801 347
E-Mail: investor_relations@biotest.de